Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have received an average rating of “Reduce” from the eight brokerages that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $23.00.

IART has been the subject of a number of analyst reports. Bank of America dropped their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Truist Financial reduced their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Morgan Stanley initiated coverage on Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price for the company. Finally, BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. KBC Group NV grew its position in Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares in the last quarter. Northwest Investment Counselors LLC purchased a new stake in shares of Integra LifeSciences during the 3rd quarter valued at $73,000. Canada Pension Plan Investment Board bought a new stake in shares of Integra LifeSciences during the 2nd quarter worth $114,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock worth $136,000 after buying an additional 1,711 shares during the last quarter. Finally, Centiva Capital LP bought a new position in Integra LifeSciences during the third quarter valued at about $192,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $22.15 on Wednesday. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42. The company has a market capitalization of $1.71 billion, a P/E ratio of -246.08, a P/E/G ratio of 0.82 and a beta of 1.16. The stock has a 50 day moving average of $23.27 and a 200-day moving average of $22.77. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the prior year, the business earned $0.76 earnings per share. The firm’s revenue for the quarter was down .4% on a year-over-year basis. As a group, equities research analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.